tetano
Editor, Senior Moderator
Vaccine
Volume 30, Issue 45, 5 October 2012, Pages 6483?6491
Cover image
Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: Data from two multicentre randomised trials
Mathieu Peetersa, 1,
Stefan Regnerb, 1, Corresponding author contact information, E-mail the corresponding author,
Tejaswini Vamanc,
Jeanne-Marie Devastera,
Lars Rombod
a GlaxoSmithKline Vaccines, Wavre, Belgium
b Gemeinschaftspraxis Mainz Mitte am Gesundheitscentrum, Mainz, Germany
c Pharmanet/I3, Inventive Health to Pharmanet/i3, inVentiv Health, Pune, India
d Department of Infectious Diseases, Center for Clinical Research, Sormland County Council, Eskilstuna, Sweden
http://dx.doi.org/10.1016/j.vaccine.2012.07.081, How to Cite or Link Using DOI
Permissions & Reprints
View full text
Purchase $31.50
Abstract
During the 2009?2010 Northern Hemisphere influenza season, both seasonal and pandemic influenza vaccines were expected to be administered to elderly people, which is an important target group for influenza vaccination. Two multicentre randomised clinical studies were conducted in participants aged ≥61 years to assess the immunogenicity and reactogenicity following vaccination with two doses of an AS03-adjuvanted A(H1N1)pmd09 vaccine when either sequentially administered (21 days before first dose [N = 73] or 21 days after second dose [N = 72]) or co-administered (first dose [N = 84] or second dose [N = 84]) with a licensed trivalent seasonal influenza vaccine (TIV). Overall, 313 participants from 2 centres in Sweden (ClinicalTrials.gov, NCT00968890) and 6 centres in Germany (NCT00971425) were randomised to one of the four treatment groups. The AS03-adjuvanted A(H1N1)pmd09 vaccine elicited a good immune response against A(H1N1)pmd09-like virus in all treatment groups after the first and second dose, meeting and exceeding the European licensing criteria for pandemic influenza vaccines. After one dose of the AS03-adjuvanted A(H1N1)pmd09 vaccine, haemagglutination inhibition seroconversion rates ranged from 85% (95% confidence interval: 74?93%) to 93% (85?97%), seroprotection rates from 87% (76?94%) to 96% (90?99%) and geometric mean fold rise from 15 (11?19) to 20 (16?25). The haemagglutination inhibition immune responses to the AS03-adjuvanted A(H1N1)pmd09 vaccine seemed lower when TIV was administered 3 weeks before, while immune responses to TIV seemed not affected by either vaccination schedule. Solicited symptoms were more frequently reported following administration of the AS03-adjuvanted A(H1N1)pmd09 vaccine compared to TIV, but these were mainly mild to moderate in intensity and transient in the four treatment groups. These results suggest that sequential or co-administration of the AS03-adjuvanted A(H1N1)pmd09 vaccine and TIV induced a good immune response to both vaccines and had a clinically acceptable safety profile in people aged ≥61 years.
Highlights
► The AS03-adjuvanted A(H1N1)pmd09 vaccine is immunogenic in people aged ≥61 years. ► Co-administration of seasonal influenza and pandemic vaccines is immunogenic. ► Sequential administration of seasonal influenza and pandemic vaccines is immunogenic. ► Both vaccines are well-tolerated following co- or sequential administration.
http://www.sciencedirect.com/science/article/pii/S0264410X12011188
Volume 30, Issue 45, 5 October 2012, Pages 6483?6491
Cover image
Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: Data from two multicentre randomised trials
Mathieu Peetersa, 1,
Stefan Regnerb, 1, Corresponding author contact information, E-mail the corresponding author,
Tejaswini Vamanc,
Jeanne-Marie Devastera,
Lars Rombod
a GlaxoSmithKline Vaccines, Wavre, Belgium
b Gemeinschaftspraxis Mainz Mitte am Gesundheitscentrum, Mainz, Germany
c Pharmanet/I3, Inventive Health to Pharmanet/i3, inVentiv Health, Pune, India
d Department of Infectious Diseases, Center for Clinical Research, Sormland County Council, Eskilstuna, Sweden
http://dx.doi.org/10.1016/j.vaccine.2012.07.081, How to Cite or Link Using DOI
Permissions & Reprints
View full text
Purchase $31.50
Abstract
During the 2009?2010 Northern Hemisphere influenza season, both seasonal and pandemic influenza vaccines were expected to be administered to elderly people, which is an important target group for influenza vaccination. Two multicentre randomised clinical studies were conducted in participants aged ≥61 years to assess the immunogenicity and reactogenicity following vaccination with two doses of an AS03-adjuvanted A(H1N1)pmd09 vaccine when either sequentially administered (21 days before first dose [N = 73] or 21 days after second dose [N = 72]) or co-administered (first dose [N = 84] or second dose [N = 84]) with a licensed trivalent seasonal influenza vaccine (TIV). Overall, 313 participants from 2 centres in Sweden (ClinicalTrials.gov, NCT00968890) and 6 centres in Germany (NCT00971425) were randomised to one of the four treatment groups. The AS03-adjuvanted A(H1N1)pmd09 vaccine elicited a good immune response against A(H1N1)pmd09-like virus in all treatment groups after the first and second dose, meeting and exceeding the European licensing criteria for pandemic influenza vaccines. After one dose of the AS03-adjuvanted A(H1N1)pmd09 vaccine, haemagglutination inhibition seroconversion rates ranged from 85% (95% confidence interval: 74?93%) to 93% (85?97%), seroprotection rates from 87% (76?94%) to 96% (90?99%) and geometric mean fold rise from 15 (11?19) to 20 (16?25). The haemagglutination inhibition immune responses to the AS03-adjuvanted A(H1N1)pmd09 vaccine seemed lower when TIV was administered 3 weeks before, while immune responses to TIV seemed not affected by either vaccination schedule. Solicited symptoms were more frequently reported following administration of the AS03-adjuvanted A(H1N1)pmd09 vaccine compared to TIV, but these were mainly mild to moderate in intensity and transient in the four treatment groups. These results suggest that sequential or co-administration of the AS03-adjuvanted A(H1N1)pmd09 vaccine and TIV induced a good immune response to both vaccines and had a clinically acceptable safety profile in people aged ≥61 years.
Highlights
► The AS03-adjuvanted A(H1N1)pmd09 vaccine is immunogenic in people aged ≥61 years. ► Co-administration of seasonal influenza and pandemic vaccines is immunogenic. ► Sequential administration of seasonal influenza and pandemic vaccines is immunogenic. ► Both vaccines are well-tolerated following co- or sequential administration.
http://www.sciencedirect.com/science/article/pii/S0264410X12011188